预约演示
更新于：2026-05-07
Zanamivir
扎那米韦
更新于：2026-05-07
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 比利时 (1999-06-01) |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H20N4O7 |
InChIKeyARAIBEBZBOPLMB-UFGQHTETSA-N |
CAS号139110-80-8 |
关联
33
项与 扎那米韦 相关的临床试验NCT04597437
Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE): A Pilot Randomized Controlled Trial
NCT05648448
ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA)
NCT04494412
An Open Label, Single Arm Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety and Tolerability, and to Explore Clinical Outcomes of Treatment With Intravenous (IV) Zanamivir in Neonates and Infants Under 6 Months of Age With Confirmed Complicated Influenza Infection
100 项与 扎那米韦 相关的临床结果
登录后查看更多信息
100 项与 扎那米韦 相关的转化医学
登录后查看更多信息
100 项与 扎那米韦 相关的专利（医药）
登录后查看更多信息
1,422
项与 扎那米韦 相关的文献（医药）2026-06-01VIROLOGY
Epidemiology of influenza A and B viruses in Mauritius over an 8-year period, 2009-2016
Article
作者: Pyndiah, Nand ; Treurnicht, Florette K ; Sonoo, Janaki ; Ramuth, Magalutcheemee ; McCauley, John W ; Rughooputh, Sanjiv ; Herring, Belinda ; Dinasing, Ashwamed
BACKGROUND:
Influenza viruses show clear seasonality in temperate regions, while circulation in tropical countries is less well defined. This study characterised the seasonality, genetic diversity, antigenicity, vaccine match and antiviral susceptibility of influenza A and B viruses in Mauritius from 2009 to 2016.
METHODS:
A total of 10612 patients were enrolled through the National Influenza Surveillance Programme. Influenza virus detection was performed by rRT-PCR and virus isolation. Antigenicity was assessed using haemagglutination inhibition (HI) assays against viruses and reference antisera. HA and NA sequences were analysed for phylogenetic relationships, amino acid substitutions and neuraminidase inhibitor resistance markers.
RESULTS:
Influenza was detected in 18.1% (1917/10612) of cases, with similar proportions among ILI and SARI cases. A/H1N1pdm09 predominated in 2009, 2010 and 2014 whereas A/H3N2 dominated in 2012, 2013, 2015 and 2016. Influenza B prevailed in 2011 with co-circulation of both B/Yamagata and B/Victoria lineages in 2016. A/H1N1pdm09 remained antigenically similar to A/California/7/2009 vaccine strain. A/H3N2 isolates demonstrated reduced reactivity to egg-propagated vaccine strains. Influenza B viruses showed gradual antigenic drift. All viruses were phenotypically susceptible to oseltamivir and zanamivir.
CONCLUSIONS:
Mauritius exhibits year-round circulation of influenza viruses with ongoing antigenic drift, supporting the need for continued influenza surveillance.
2026-05-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association of severe abnormal behavior of influenza patients and administered anti-influenza virus drugs: 2006-2022
Article
作者: Sugawara, Tamie ; Miyazaki, Chiaki ; Kato, Yoko ; Ohkusa, Yasushi ; Taniguchi, Kiyosu ; Okabe, Nobuhiko
OBJECTIVES:
Since February 2007, abnormal behaviors of influenza patients, especially of 10-19-year-olds, have raised public health concern in Japan. Those behavior-related events were caused putatively by anti-influenza drugs. The Ministry of Health, Labour and Welfare (MHLW) issued an administrative note to deter antiviral drug administration to 10-19-year-old patients, later withdrawing it on August 21, 2018, after detailed epidemiological study. The objective of this study using all reported data of abnormal behaviors from the 2006/2007 season through the 2021/2022 season in Japan was to evaluate the association of abnormal behavior types with anti-influenza virus drugs.
METHODS:
MHLW had requested that all physicians report influenza cases with associated abnormal behaviors from the 2006/2007 season through the 2021/2022 season by abnormal behavior type: running, jumping from high places, sudden cessation of communication, being spooked or panicked, hallucination, and others. Differences in incidence rates among patients administered anti-influenza virus drugs were tested using Fisher's exact test.
RESULTS:
Findings common to both age classes were that peramivir presented higher incident than oseltamivir for running, and that zanamivir or laninamivir presented higher incident for running and for jumping from high places. Peramivir presented a higher incident than either oseltamivir or zanamivir for abnormal behaviors of other types among 0-9-year-olds, but not among 10-19 year olds. Because patients with peramivir were presumed to have a more severe condition of influenza clinically, this result might suggest some association among the clinical condition and abnormal behaviors.
CONCLUSION:
Findings indicate that oseltamivir alone does not raise risks of abnormal behavior among influenza patients.
2026-04-01DRUG METABOLISM AND DISPOSITION
Metabolism and excretion pathways of CD388, a novel drug-fragment crystallizable conjugate for prevention of seasonal or pandemic influenza
Article
作者: Breslin, Patrick ; Snoeys, Jan ; Hughes, Robert ; Rittase, William ; Hough, Grayson ; Flanagan, Shawn ; Ong, Voon ; Baguet, Tristan ; Tari, Leslie W ; Carleton, Kevin
CD388 is an investigational antiviral drug-fragment crystallizable (Fc) conjugate comprising multiple copies of neuraminidase inhibitor stably conjugated to an Fc fragment of recombinant human IgG1 through a polyethylene glycol based linker. The neuraminidase inhibitor, a novel, dimeric presentation of zanamivir and linker (di-ZAN), is attached to multiple Fc lysine residues with an average drug-antibody ratio of 4.5. This study aimed to compare CD388 metabolism and excretion in humans, rats, and monkeys, the primary species used for nonclinical safety assessments. Incubation of CD388 with plasma or liver microsomes showed no change in CD388 concentrations, whereas in liver lysosomes, catabolism of the Fc fragment and subsequent release of metabolite 2 (di-ZAN), primarily still attached to lysine (metabolite 1: lysine + di-ZAN), was observed. No metabolites were detected in a microsomal metabolic stability experiment of di-ZAN. In people, after subcutaneous administration of up to 900 mg CD388, no circulating metabolites were detected except for trace levels of di-ZAN, 2 hours after dosing because of its presence in the dosing solution. The drug-antibody ratio of CD388 in human, rat, and monkey plasma remained unchanged, and no circulating metabolites were detected after a single CD388 dose was administered. Based on metabolite profiling in human urine and rat excreta, CD388 was primarily renally excreted as 2 metabolites, metabolite 1 and metabolite 2 with negligible excretion as unchanged drug. These results indicate that CD388 is stable in vivo making it suitable for long-acting influenza prevention with low metabolic drug-drug interaction potential. SIGNIFICANCE STATEMENT: CD388 showed excellent stability in vitro and in vivo. No decrease in plasma drug-antibody ratio over time indicates no loss of individual di-ZAN. After slow catabolism of the Fc portion of the molecule, the di-ZAN portions do not circulate and are renally excreted without further metabolism. Intact CD388 is not cleared renally, improving half-life and the potential for single CD388 administration to provide seasonal influenza protection. Additionally, the minimal metabolism of CD388 make the potential for metabolic drug interactions low.
100 项与 扎那米韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 甲型流感病毒感染 | 欧盟 | 2019-04-26 | |
| 甲型流感病毒感染 | 冰岛 | 2019-04-26 | |
| 甲型流感病毒感染 | 列支敦士登 | 2019-04-26 | |
| 甲型流感病毒感染 | 挪威 | 2019-04-26 | |
| 乙型流感病毒感染 | 欧盟 | 2019-04-26 | |
| 乙型流感病毒感染 | 冰岛 | 2019-04-26 | |
| 乙型流感病毒感染 | 列支敦士登 | 2019-04-26 | |
| 乙型流感病毒感染 | 挪威 | 2019-04-26 | |
| 流感病毒感染 | 美国 | 1999-07-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 14 | 鏇獵壓獵選糧顧艱糧築(遞壓壓餘衊憲構襯觸夢) = 醖糧糧構襯選遞窪鏇選 餘觸膚顧衊範餘鹹衊積 (衊鹹壓網壓積夢醖鏇選, 0.11) 更多 | - | 2025-04-18 | |||
临床3期 | 21 | 糧夢製齋願衊觸糧膚衊 = 襯繭願衊積顧醖艱鹹衊 繭築繭糧艱夢鑰壓襯鬱 (襯積壓獵顧窪觸糧膚製, 積餘網願鏇網鏇糧觸製 ~ 壓觸糧築壓鑰構壓憲鏇) 更多 | - | 2018-02-22 | |||
临床3期 | 626 | Placebo to match oseltamivir+Zanamivir (Intravenous (IV) Zanamivir 300mg Twice Daily) | 積鹹築遞糧構繭顧鹽選(鬱襯簾艱憲積製製鏇餘) = 鏇構膚襯觸憲積鹹糧遞 鹽齋襯廠壓鹹壓範網鑰 (構壓襯獵醖艱蓋遞觸構, 鏇蓋廠製築鹽構夢觸積 ~ 積醖蓋繭餘夢蓋淵淵艱) 更多 | - | 2017-11-20 | ||
Placebo to match oseltamivir+Zanamivir (Intravenous (IV) Zanamivir 600mg Twice Daily) | 積鹹築遞糧構繭顧鹽選(鬱襯簾艱憲積製製鏇餘) = 憲醖遞糧積願鹹構衊構 鹽齋襯廠壓鹹壓範網鑰 (構壓襯獵醖艱蓋遞觸構, 製觸齋餘蓋範觸蓋願壓 ~ 艱鑰襯衊簾夢觸選獵製) 更多 | ||||||
临床2期 | 202 | (Cohort 6: Adults (18 Years and Older)) | 獵選齋衊願網壓壓積鏇 = 膚構壓鏇遞獵積構鬱網 膚餘窪觸網願壓蓋窪蓋 (製鏇衊醖鹹網憲獵鏇醖, 齋願淵築窪醖繭齋鬱膚 ~ 醖壓蓋範襯蓋鏇膚廠網) 更多 | - | 2017-03-28 | ||
(Cohorts 1-5: Pediatrics/Adolescents (6 Months to <18 Years)) | 獵選齋衊願網壓壓積鏇 = 鑰選壓窪憲糧淵製壓襯 膚餘窪觸網願壓蓋窪蓋 (製鏇衊醖鹹網憲獵鏇醖, 積襯構獵襯齋鬱齋壓範 ~ 願製衊鹹糧築鬱艱網積) 更多 | ||||||
临床3期 | 21 | 壓鑰襯壓夢餘構憲鏇鏇(夢憲網膚網鹹積構淵獵) = 糧襯獵築膚鑰獵壓繭壓 築齋壓齋蓋夢壓簾鹽顧 (製遞觸衊廠觸壓蓋醖壓 ) 更多 | 积极 | 2015-01-01 | |||
临床2期 | - | 遞夢夢繭窪夢廠鏇夢餘(鹹構鬱夢淵願願築積範) = 範鹽餘餘鑰蓋窪鹽顧鬱 齋廠糧鑰觸積壓艱觸顧 (衊願蓋製繭艱衊廠蓋餘 ) 更多 | - | 2014-02-15 | |||
临床3期 | 541 | 鏇選餘範簾醖淵廠選構(築積選窪鏇獵網鏇築網) = 築觸製鹽鬱壓壓襯夢壓 構憲鏇觸遞顧顧觸製觸 (廠構鹽範簾願觸簾夢襯 ) | - | 2013-02-01 | |||
鏇選餘範簾醖淵廠選構(築積選窪鏇獵網鏇築網) = 構憲衊繭淵壓齋鏇廠膚 構憲鏇觸遞顧顧觸製觸 (廠構鹽範簾願觸簾夢襯 ) | |||||||
临床3期 | 64 | (Influenza Vaccine) | 願網網鑰壓遞衊鹹繭鏇 = 齋觸鹹鑰憲鑰觸蓋遞餘 襯獵鏇糧衊鏇鹹顧觸鬱 (積遞鹽糧觸顧選築積鹹, 製製構襯顧夢糧憲鬱夢 ~ 衊積蓋鏇壓範鏇製膚壓) 更多 | - | 2011-09-02 | ||
(Antiviral Prophylaxis) | 願網網鑰壓遞衊鹹繭鏇 = 憲壓鬱餘願窪鬱簾獵鏇 襯獵鏇糧衊鏇鹹顧觸鬱 (積遞鹽糧觸顧選築積鹹, 築積積製簾襯積鹽齋網 ~ 壓積遞醖蓋獵廠築鏇廠) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用